ArticleJAMA network open2024
Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder.
Abstract read
In one paragraph
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era.Drug and alcohol dependence reports · 2026Review
- Methodological innovations to advance substance use disorder research: Proceedings of a NIDA workshop on target trial emulation and translational testing of digital health tools.Journal of substance use and addiction treatment · 2026Article
- Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.Behavioural pharmacology · 2026Article
- GLP-1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation.Obesity (Silver Spring, Md.) · 2026Observational
- GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.The Journal of clinical psychiatry · 2026Article
- How Negative Controls Are Used in Pharmacoepidemiology: A Methodological Scoping Review of Real-World Observational Studies of Glucagon-Like Peptide-1 Receptor Agonists.Pharmacoepidemiology and drug safety · 2026Article
- A rapid review of the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes.Drug and alcohol dependence reports · 2026Review
- GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes.Journal of general internal medicine · 2026Article
- Spironolactone and clinical outcomes in patients with alcohol use disorder and comorbid hypertension: a target trial emulation study.Psychopharmacology · 2026Article
- Beyond Glycemic Control: GLP-1RA-Based Therapies and Emerging Targets Beyond the Metabolic Axis.Journal of clinical medicine · 2026Review
- Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.BMJ (Clinical research ed.) · 2026Article
- Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.Journal of clinical medicine · 2026Review
- Emerging and Off-Label Uses Of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and Dual GIP/GLP1-RAs.Journal of the American Board of Family Medicine : JABFM · 2026Article
- Prehospital glucagon-like peptide-1 receptor agonists are not associated with reduced inpatient opioid exposure but with shorter hospital length of stay after total joint arthroplasty.Frontiers in endocrinology · 2026Article
- Novel pharmacotherapies for opioid use disorder and opioid withdrawal.Frontiers in psychiatry · 2026Review
- GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Review
- Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.Diabetes, obesity & metabolism · 2025Article
- Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon.Journal of internal medicine · 2025Review
- GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer.Journal of the Endocrine Society · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
William WangCenter for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Nora D VolkowNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
QuangQiu WangCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Nathan A BergerCenter for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Pamela B DavisCenter for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, Ohio.
David C KaelberCenter for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio.
Rong XuCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Funding
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1MCombine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's DiseaseR01AG061388 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., XU, RONG · 2018 to 2022
$3.4MAn Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's DiseaseR01AG057557 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2017 to 2021
$2.8MConstruct large-scale phenomes of disease and drugs and develop data-driven systems approaches to understand genetic links between Alzheimer's disease and Neuropsychiatric symptomsR56AG062272 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2018 to 2019
$1.6MNCATS NIH HHS UM1 TR004528NIA NIH HHS R01 AG057557NIA NIH HHS R01 AG061388NIA NIH HHS R56 AG062272
Abstract
PubMed holds no abstract for this paper.
Indexed as
Diabetes Mellitus, Type 2Glucagon-Like PeptidesOpiate OverdoseOpioid-Related DisordersAdultFemaleHumansHypoglycemic AgentsMaleMiddle AgedSemaglutideGlucagon-Like PeptidesHypoglycemic AgentsSemaglutide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.